P/E ratio for Zydus Lifesciences (ZYDUSLIFE.NS)
P/E ratio as of April 2024 (TTM): 37.5
According to Zydus Lifesciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 37.5422. At the end of 2022 the company had a P/E ratio of 20.7.
P/E ratio history for Zydus Lifesciences from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 20.7 | 100.08% |
| 2021 | 10.4 | -59.98% |
| 2020 | 25.9 | 24.02% |
| 2019 | 20.9 | 15.98% |
| 2018 | 18.0 | -36.06% |
| 2017 | 28.2 | 29.18% |
| 2016 | 21.8 | 11.68% |
| 2015 | 19.5 | -38.05% |
| 2014 | 31.5 | 57.15% |
| 2013 | 20.1 | -38.9% |
| 2012 | 32.8 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.